First, second kidney transplants have similar success: study

(HealthDay) -- One failed kidney transplant doesn't mean a second transplant is likely to fail, according to a new study that found similar kidney survival, rejection and infection rates in people who undergo repeat transplants compared to patients who have had just one.

"Second transplants have traditionally been considered a high immunologic risk, but there's been a lack of data on outcomes of re-transplants," said the study's leader, Dr. Syed Jawad Sher, at the Indiana University School of Medicine, in a National Kidney Foundation news release. "Our study, which was controlled for donor factors making the findings reliable, shows that re-transplants can be equally successful."

The researchers examined 38 cases where one kidney of a deceased donor was transplanted into a patient receiving a primary transplant, and the other was donated to a patient receiving a repeat transplant.

One- and five-year kidney graft survival rates were similar, according to the researchers, who also found no differences in the rate of bacterial or . Advances in medications to suppress the might be responsible for increasing success of repeat transplants, Sher said.

"The message to kidney specialists is that they can feel comfortable referring patients with failed transplants for a second evaluation. This study also gives hope to patients that they have a very good likelihood of success the second time around," said Dr. Lynda Szczech, president of the , in the release.

The study's findings were expected to be presented Thursday at the foundation's annual meeting, in Washington, D.C. The data and conclusions should be viewed as preliminary until published in a peer-reviewed journal.

More information: The U.S. National Institutes of Health provides more information on kidney transplants.

add to favorites email to friend print save as pdf

Related Stories

Recommended for you

Amgen misses 1Q views as higher costs cut profit

Apr 22, 2014

Despite higher sales, biotech drugmaker Amgen's first-quarter profit fell 25 percent as production and research costs rose sharply, while the year-ago quarter enjoyed a tax benefit. The company badly missed ...

Valeant, Ackman make $45.6B Allergan bid

Apr 22, 2014

Valeant Pharmaceuticals and activist investor Bill Ackman have unveiled details of their offer to buy Botox maker Allergan, proposing a cash-and-stock deal that could be worth about $45.6 billion.

User comments